二甲双胍 (Metformin) 指南 (2026)
完整指南与实证研究 (2026)
二甲双胍是二型糖尿病的一线药物，目前正因其长寿潜力（TAME 临床试验）而备受关注。它能激活 AMPK，降低胰岛素/IGF-1 信号，并具有抗癌特性。
二甲双胍的作用机制
AMPK Activation
Activates the cellular energy sensor AMPK. Mimics caloric restriction signaling. Reduces hepatic glucose production
mTOR Inhibition
Indirectly inhibits mTORC1 via AMPK. Promotes autophagy — cellular cleanup. Reduces protein synthesis — longevity signal
Metabolic Effects
Improves insulin sensitivity. Lowers fasting glucose and HbA1c. Mild reduction in body weight (1–3 kg)
关键数据
全球目前正在服用二甲双胍的患者人数——它是处方量最大的糖尿病药物。
具有里程碑意义的“用二甲双胍靶向衰老 (TAME)”人体试验中测试的剂量。
在不补充维生素的情况下，长期服用二甲双胍的用户中出现 B12 缺乏的比例。
二甲双胍方案概览
监测：每年检查 B12 水平、eGFR（肾小球滤过率）和 HbA1c。避免在剧烈运动当天服用（尚存争议），并在进行造影检查前停药。使用缓释剂型以减少胃肠道副作用。
二甲双胍长寿研究时间线
二甲双胍首次在法国被描述。1958 年起在欧洲用于治疗二型糖尿病 (T2D)。
《新英格兰医学杂志》(NEJM) 论文：服用二甲双胍的糖尿病患者寿命超过了匹配的非糖尿病患者——这是里程碑式的长寿信号。
FDA 批准 TAME（用二甲双胍靶向衰老）试验方案——这是首个获 FDA 批准的衰老干预试验。
TAME 试验正在招募约 3,000 名 65-79 岁的健康成年人。结果预计于 2027 年公布。
核心方案常见问题
Why are healthy people taking metformin for longevity?
Metformin, the most prescribed diabetes drug in the world, has attracted longevity interest because of its AMPK activation (same pathway as caloric restriction), mTOR inhibition, and observational dat
What is the metformin longevity dose?
For longevity purposes (off-label), physicians typically prescribe 500–1000 mg/day, often taken at night or with meals to minimize GI side effects. The TAME trial uses 1500 mg/day. Diabetic doses go u
Does metformin interfere with exercise adaptations?
This is a genuine controversy. A 2023 study showed high-dose metformin blunted some exercise adaptations (VO2max gains) in older adults. However, lower doses and specific timing (avoiding pre-workout
Is metformin safe for non-diabetics?
Metformin has a very long safety record with billions of patient-years of use in diabetics. The primary risk in non-diabetics is hypoglycemia (rare at low doses) and vitamin B12 depletion with long-te
指南常见问题
它是二型糖尿病的一线药物，目前正因其长寿潜力（TAME 临床试验）而备受关注。它能激活 AMPK，降低胰岛素/IGF-1 信号，并具有抗癌特性。
可以。Shotlee 支持追踪二甲双胍的剂量、副作用和健康指标。该功能可免费使用。
参考文献
- [1]Clinical TrialUK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865.
- [2]Clinical TrialKnowler WC et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin (DPP). N Engl J Med. 2002;346(6):393-403.